The information in this section is intended for visitors outside the United States.
ONO and Gilead Announce Exclusive License Agreement to Develop BTK Inhibitor, ONO-4059, for the Treatment of B-cell Malignancies and Other Diseases
Philippe C. Bishop, MD, to Join Gilead as Senior Vice President, Hematology and Oncology Therapeutics
Gilead Presents Follow-up Data from Zydelig Registrational Studies in Patients with Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma
2013 Annual Review